INTRODUCTION Propan-2-yl 2-[(4-chlorophenyl) carbonyl] phenoxymethyl propanoate is the chemical name for fenofbrate (FEN) (Figure 1). 1 People at risk for cardiovascular disease primarily use it to lower cholesterol levels. Like other fbrates, it raises high- density lipoprotein (HDL) levels, reduces triglycerides, and lowers low density lipoprotein (LDL) and very low density lipoprotein (VLDL) cholesterol levels. It also lowers levels of LDL and VLDL cholesterol. 2 The drug is a white in colour that is soluble in acetone, acetone dimethyl sulfoxide, methanol, dimethylformamide, and water only very slightly. 3 Following a thorough review of the literature, it was discovered that numerous high-performance liquid chromatography (HPLC) methods were published used for the quantification of fenofbrate in both formulations. 4-19 As a result, pharmaceutical scientists may fnd it challenging to implement an analytical methodology to identify FEN in the existence of its deprivation yields. Since the recommended technique is simple, accurate, repeatable, and simple for regular estimation of FEN in both formulations. According to intracerebral brain hemorrhage (ICH) recommendations, the procedure was validated. 20 METHODOLOGY Chemicals and Reagents Pharmacological quality fenolip-145, a tablet formulation, was purchased commercially from Cadila Pharmaceuticals Ltd., Ahmedabad, as a gift sample of fenofbrate. O Cl O O CH 3 O CH 3 CH 3 C H 3 Figure 1: Fenofbrate (Chemical structure). ABSTRACT Very simple, exact, precise and accurate reversed-phase high-performance liquid chromatography (RP-HPLC) methods used to estimate the amount of fenofbrate in both the bulk and tablet formulations. The reversed-mobile phase bufer and ACN in the proportion (40:60) v/v at a fow rate of 1.0 mL/min were used to create the Princeton (C18) (250 mm x 4.6 mm, 5) column. At 240 nm wavelength, the detection procedure was approved. The RT was established to be 3.905 minutes under fenofbrate’s optimum circumstances. The calibration curve had a range of 87 to 232 g/mL and a correlation coefcient of 0.9994. All-important parameters’ RSD values were below 2.0%. A 99.13 and a 100.44% recovery rate, respectively, were shown to exist. In accordance with ICH requirements, the established technique was evaluated for linearity, specifcity, precision, accuracy, and system applicability. The feasibility and repeatability of the suggested technique for determining the amount of the commercially available dosage forms of fenofbrate in tablet and bulk form were also demonstrated. Keywords: Fenofbrate, Reversed-phase high-performance liquid chromatography, Intracerebral brain hemorrhage guidelines, Validation. International Journal of Drug Delivery Technology (2022); DOI: 10.25258/ijddt.12.4.22 How to cite this article: Pimpale A, Gunde M, Kakde R, Kakde I. Development and Validation for the Estimation of Fenofbrate in Pharmaceutical Dosage form by Reversed-phase High-performance Liquid Chromatography. International Journal of Drug Delivery Technology. 2022;12(4):1608-1611. Source of support: Nil. Confict of interest: None Development and Validation for the Estimation of Fenofbrate in Pharmaceutical Dosage form by Reversed-phase High-performance Liquid Chromatography Awdhut Pimpale 1 *, Mahendra Gunde 1 , Rajendra Kakde 2 , Ishwar Kakde 3 1 Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education & Research (Deemed University), Wardha, Maharashtra, India 2 Department of Pharmaceutical Sciences, RTM Nagpur University, Nagpur, Maharashtra, India 3 Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune, Maharashtra, India Received: 20 th October, 2022; Revised: 22 nd November, 2022; Accepted: 09 th December, 2022; Available Online: 25 th December, 2022 RESEARCH ARTICLE *Author for Correspondence: adityapimpale@gmail.com